Compare iShares Self-Driving EV and Tech (IDRV) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Self-Driving EV and Tech vs Inovio Pharmaceuticals Inc — how do they compare? iShares Self-Driving EV and Tech trades at $36.06, while Inovio Pharmaceuticals Inc trades at $1.08 (market cap $90.50M). The key difference: iShares Self-Driving EV and Tech is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| IDRV | INO | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $45.48 | $2.87 |
52-Week Low | $32.13 | $1.05 |
Market Cap | — | $90.50M |
Enterprise Value | — | $61.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDRV trades at $35.67, down 1.22% for the day, with a bearish technical signal from moving averages and oscillators. The stock faces resistance near $36 and support at $35. Recent news highlights strong global EV sales growth and China's expanding market ambitions, though U.S. adoption lags. A dividend of $0.30 is scheduled for June 2026.
The outlook for IDRV is clouded by technical weakness and competitive pressures, but long-term EV adoption trends offer potential. Key risks include regulatory hurdles and market volatility. Investors should weigh the bearish signals against sector growth catalysts.
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
